Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer

OBJECTIVE: The objective of this open-label, randomized study was to compare dose-dense paclitaxel plus carboplatin (PCdd) with dose-dense epirubicin and cyclophosphamide followed by paclitaxel (ECdd-P) as an adjuvant chemotherapy for early triple-negative breast cancer (TNBC). METHODS: We included...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Chin J Cancer Res
Main Authors: Li, Qing, Wang, Jiani, Mu, Yuxin, Zhang, Tongtong, Han, Ying, Wang, Jiayu, Li, Qiao, Luo, Yang, Ma, Fei, Fan, Ying, Zhang, Pin, Xu, Binghe
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2020
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7491545/
https://ncbi.nlm.nih.gov/pubmed/32963461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2020.04.06
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki